ABVC Receives US$250,000 From ForSeeCon; Vitargus(R) Total Licensing Fee up to US$33.5 Million; US$816,000 Already ReceivedSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ABVC Receives US$250,000 From ForSeeCon; Vitargus(R) Total Licensing Fee up to US$33.5 Million; US$816,000 Already ReceivedSILICON VALLEY, CA - November 21, 2025 ( NEWMEDIAWIRE ) - ABVC BioPharma, Inc. (“ ABVC ” or the “ Company ”) (
NASDAQ: ABVC) announced today that ForSeeCon Eye Corporation (“ ForSeeCon ”) has made an additional US$250,000 payment under the existing ophthalmic medical device licensing agreement (the “ Licensing Agreement ”). To date, ABVC has received US$816,000 in total payments from ForSeeCon in connection with the Licensing Agreement.
ABVC BioPharma Receives US$240,000 Licensing Payment From OncoX BioPharma; Total Licensing Payments Reach Approximately US$2.53 MillionSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ABVC BioPharma Receives US$240,000 Licensing Payment From OncoX BioPharma; Total Licensing Payments Reach Approximately US$2.53 MillionSILICON VALLEY, CA - November 18, 2025 ( NEWMEDIAWIRE ) - ABVC BioPharma, Inc. (
NASDAQ: ABVC) (“ABVC” or the “Company”) today announced that it has received an additional US$240,000 licensing payment from its partner OncoX BioPharma, Inc. (“OncoX”) under their existing licensing agreement.
BioKey Stands as a Strategic U.S. Pharmaceutical Platform Amid Global Tariff ShiftsABVC’s 28,000 sq ft Silicon Valley Manufacturing Facility Stands Ready as Global Supply Chains Realign and Trust-based Localization Becomes Key
ABVC BioPharma Reports 230% YoY Licensing Revenue Growth and 181% Asset Expansion in Q3 2025Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ABVC BioPharma Reports 230% YoY Licensing Revenue Growth and 181% Asset Expansion in Q3 2025SILICON VALLEY, CA - November 3, 2025 ( NEWMEDIAWIRE ) - ABVC BioPharma, Inc. . (
NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in central nervous system (CNS), ophthalmology, and oncology/hematology indications, today announced its financial results for the quarter ended September 30, 2025, and provided an update on recent corporate developments.
ABVC BioPharma Receives Additional US$100,000 Licensing Payment from OncoX BioPharma, Bringing Total Payments to US$695,950Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ABVC BioPharma Highlighted by U.S. Financial Media as One of the Best Biotech Investments; Q3 Licensing Revenue Reaches $1.27 Million, With Clear Clinical Progress Across CNS and OncologySILICON VALLEY, CA - October 17, 2025 ( NEWMEDIAWIRE ) - ABVC BioPharma, Inc. (
NASDAQ: ABVC) (“ABVC” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies in oncology, ophthalmology, and central nervous system (CNS) disorders was recently highlighted by Insider Monkey [1] as one of the “Best Biotech Penny Stocks,” to invest in now, recognizing the company’s financial growth and advancing pipeline.
ABVC BioPharma Has Received a Cumulative Total of US$566,000 Under ForSeeCon Licensing Agreement Supporting GMP Facility in Hsinchu for Vitargus(R) ProductionSILICON VALLEY, CA - October 8, 2025 ( NEWMEDIAWIRE ) - ABVC BioPharma, Inc. (
NASDAQ: ABVC) (“ABVC” or the “Company”) today announced that it has received a US$70,000 licensing payment from its partner, ForSeeCon Eye Corporation (“ForSeeCon”), under their global licensing agreement for Vitargus®, the world’s first biodegradable vitreous substitute. With this latest payment, ForSeeCon has now paid a cumulative total of US$566,000 to ABVC under the agreement, which carries a potential value of up to US$30 million in equity consideration [1] , US$3.5 million in cash licensing payments, plus up to US$60 million in future royalties - representing a total potential value of up to US$93.5 million.
ABVC BioPharma Reports US$1.03 Million in Total Licensing Revenues Collected in Q3 to Date, Highlighting High-Margin Business ModelSILICON VALLEY, CA - September 19, 2025 ( NEWMEDIAWIRE ) - ABVC BioPharma, Inc. . (
NASDAQ: ABVC) (“ABVC” or the “Company”) today announced that it has received a licensing payment of US$145,950 from OncoX BioPharma, Inc. (“OncoX”) under the terms of the parties’ global licensing agreement. With this latest payment, ABVC has collected a total of US$595,950 from OncoX in Q3 2025, contributing to the Company’s total consolidated licensing revenues from all strategic partners of US$1,275,950 for the third quarter to date across multiple partnerships, including AiBtl BioPharma, ForSeeCon Eye Corporation, and OncoX.
ABVC BioPharma Reports US$1.03 Million in Total Licensing Revenues Collected in Q3 to Date, Highlighting High-Margin Business ModelSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ABVC BioPharma Receives $450,000 in Licensing Payments From OncoX BioPharma in Q3 2025Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ABVC BioPharma Receives $450,000 in Licensing Payments From OncoX BioPharma in Q3 2025SILICON VALLEY, CA - August 29, 2025 ( NEWMEDIAWIRE ) - ABVC BioPharma, Inc. (
NASDAQ: ABVC) (“ABVC” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies in oncology, ophthalmology, and central nervous system (CNS) disorders, today announced that its partner OncoX BioPharma has delivered $450,000 in licensing payments in the third quarter of 2025, including $350,000 received in August . These payments underscore the strength of the companies’ strategic alliance and the growing commercial potential of ABVC’s oncology pipeline.
BioLite, Inc., an ABVC BioPharma Subsidiary, Receives $230,000 Milestone Payment from AiBtl, Advancing Botanical Drug Licensing CollaborationSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
BioLite, Inc., an ABVC BioPharma Subsidiary, Receives $230,000 Milestone Payment from AiBtl, Advancing Botanical Drug Licensing CollaborationSilicon Valley, CA - ( NewMediaWire ) - August 27, 2025 - ABVC BioPharma, Inc. (
NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, today announced that one of its subsidiaries, BioLite, Inc., received an additional $230,000 milestone payment from AiBtl BioPharma, Inc. (“AiBtl”) under the strategic licensing agreement for ABV-1504 and ABV-1505, two botanical-derived drug candidates being developed for Major Depressive Disorder (MDD) and Attention-Deficit/Hyperactivity Disorder (ADHD).
ABVC BioPharma Receives $100,000 Milestone Payment From ForSeeCon, Strengthening Vitargus(R) Licensing DealSILICON VALLEY, CA - August 22, 2025 ( NEWMEDIAWIRE ) - ABVC BioPharma, Inc. (
NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, today announced that it has received an additional $100,000 licensing payment from ForSeeCon Eye Corporation (“ForSeeCon”) under the global licensing agreement covering the Company’s innovative vitreous substitute, Vitargus® .
ABVC BioPharma Receives $100,000 Milestone Payment From ForSeeCon, Strengthening Vitargus(R) Licensing DealSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ABVC BioPharma, Inc. Reports 103% Year-Over-Year Asset Growth and Secures $350K in Post-Quarter Licensing Revenue in Q2 2025Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ABVC BioPharma, Inc. Reports 103% Year-Over-Year Asset Growth and Secures $350K in Post-Quarter Licensing Revenue in Q2 2025SILICON VALLEY, CA - August 14, 2025 ( NEWMEDIAWIRE ) - ABVC BioPharma, Inc. (
NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, central nervous system (CNS) disorders, and oncology/hematology, today announced its financial results for the second quarter ended June 30, 2025. The Company continues to advance strategic initiatives aimed at stabilizing operations, strengthening its balance sheet, and building long-term shareholder value across its global platform.
BioKey Stands as a Strategic U.S. Pharmaceutical Platform Amid Global Tariff ShiftsSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ABVC BioPharma Gains Confidence From International Investors to Support Growth PathSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
